DE60330044D1 - Il-21-produktion in prokaryontischen wirten - Google Patents

Il-21-produktion in prokaryontischen wirten

Info

Publication number
DE60330044D1
DE60330044D1 DE60330044T DE60330044T DE60330044D1 DE 60330044 D1 DE60330044 D1 DE 60330044D1 DE 60330044 T DE60330044 T DE 60330044T DE 60330044 T DE60330044 T DE 60330044T DE 60330044 D1 DE60330044 D1 DE 60330044D1
Authority
DE
Germany
Prior art keywords
coli
hostes
prokaryontic
production
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60330044T
Other languages
English (en)
Inventor
Chung Chang
Bruce L Zamost
Douglas C Covert
Hong Y Liu
Jongh Karen S De
Jeffrey D Meyer
Susan D Holderman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Application granted granted Critical
Publication of DE60330044D1 publication Critical patent/DE60330044D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
DE60330044T 2002-12-13 2003-12-12 Il-21-produktion in prokaryontischen wirten Expired - Lifetime DE60330044D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43345202P 2002-12-13 2002-12-13
US43344802P 2002-12-13 2002-12-13
PCT/US2003/039764 WO2004055168A2 (en) 2002-12-13 2003-12-12 Il-21 production in prokaryotic hosts

Publications (1)

Publication Number Publication Date
DE60330044D1 true DE60330044D1 (de) 2009-12-24

Family

ID=32600150

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60330044T Expired - Lifetime DE60330044D1 (de) 2002-12-13 2003-12-12 Il-21-produktion in prokaryontischen wirten

Country Status (17)

Country Link
US (4) US7250274B2 (de)
EP (1) EP1573006B1 (de)
JP (1) JP4664684B2 (de)
KR (1) KR101098897B1 (de)
AT (1) ATE448298T1 (de)
AU (1) AU2003302250B2 (de)
BR (1) BR0317243A (de)
CA (1) CA2507817C (de)
DE (1) DE60330044D1 (de)
DK (1) DK1573006T3 (de)
ES (1) ES2334127T3 (de)
IL (2) IL168697A (de)
MX (1) MXPA05006117A (de)
NO (1) NO334561B1 (de)
PL (1) PL209009B1 (de)
RU (1) RU2354703C2 (de)
WO (1) WO2004055168A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
WO2004112703A2 (en) * 2003-06-19 2004-12-29 Centocor, Inc. Interleukin-21 analogs
EP2263684A1 (de) 2003-10-10 2010-12-22 Novo Nordisk A/S IL-21 Derivate
US20060228331A1 (en) * 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
EP2641611A3 (de) * 2003-10-17 2013-12-18 Novo Nordisk A/S Kombinationstherapie
EP2425847A1 (de) * 2004-05-20 2012-03-07 ZymoGenetics, Inc. Verfahren zur Behandlung von Krebs mittels Therapie mit IL-21- und monoklonaler Antikörper
MX2007012887A (es) 2005-04-18 2007-12-10 Novo Nordisk As Variantes il-21.
WO2006125821A2 (en) * 2005-05-26 2006-11-30 Cytos Biotechnology Ag Scalable fermentation process
BRPI0611251A2 (pt) * 2005-06-06 2010-12-07 Novo Nordisk As composição, métodos para estabilizar uma composição compreendendo il-21, para redobrar il-21 não dobrada ou parcialmente dobrada em solução, para purificar il-21 e para tratar cáncer, e, uso de il-21 e sulfato
EP1924601B1 (de) 2005-08-30 2011-10-19 Novo Nordisk A/S Expression von proteinen in e.coli
WO2007039147A1 (en) 2005-09-22 2007-04-12 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods of using il-21
ES2357152T3 (es) * 2005-10-04 2011-04-19 Zymogenetics, L.L.C. Producción y purificación de il-29.
DK1963369T3 (da) * 2005-11-28 2013-06-03 Zymogenetics Inc Il-21-antagonister
JP5401097B2 (ja) 2005-12-23 2014-01-29 ノボ・ノルデイスク・エー／エス 分取逆相クロマトグラフィー（ｒｐｃ）を使用するタンパク質精製
EP2061897B1 (de) * 2006-07-27 2020-03-25 Wyeth LLC Fed-batch-fermentierungsverfahren mit hoher zellendichte zur herstellung eines rekombinanten proteins
JP2010507382A (ja) 2006-10-26 2010-03-11 ノヴォ ノルディスク アクティーゼルスカブ Ｉｌ−２１変異体
AU2007336184A1 (en) 2006-12-21 2008-06-26 Novo Nordisk A/S Interleukin-21 variants with altered binding to the IL-21 receptor
CN101622269A (zh) * 2007-03-01 2010-01-06 诺沃-诺迪斯克有限公司 蛋白质在大肠杆菌中的表达
JP5358840B2 (ja) * 2007-11-24 2013-12-04 独立行政法人産業技術総合研究所 Ｇｆｐ（緑色蛍光蛋白質）の機能賦活・回復方法
WO2010055366A2 (en) 2007-12-07 2010-05-20 Zymogenetics, Inc. Anti-human il-21 monoclonal antibodies
US9927440B2 (en) * 2009-11-25 2018-03-27 Duke University Protein engineering
US9556247B2 (en) * 2010-05-25 2017-01-31 System Of Systems Analytics, Inc. Stabilized amyloid-beta oligomers and uses thereof
WO2013169693A1 (en) 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
JP6086378B2 (ja) * 2012-11-30 2017-03-01 国立大学法人お茶の水女子大学 組み換えヒト膵臓リパーゼの調製方法
JPWO2015178466A1 (ja) * 2014-05-21 2017-04-20 味の素株式会社 フィブロイン様タンパク質の製造法
RU2620073C2 (ru) * 2015-06-02 2017-05-22 Федеральное государственное бюджетное учреждение "Государственный научный центр Институт иммунологии" Федерального медико-биологического агентства России Оптимизированный ген, кодирующий рекомбинантный белок - аналог интерферона альфа-17 человека
RU2614264C2 (ru) * 2015-06-19 2017-03-24 Федеральное государственное бюджетное учреждение "Государственный научный центр Институт иммунологии" Федерального медико-биологического агентства России Оптимизированный ген, кодирующий рекомбинантный белок - аналог интерферона бета человека
RU2614124C9 (ru) * 2015-10-01 2020-04-22 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) Оптимизированный ген, кодирующий рекомбинантный белок ипфiii
JP2017110001A (ja) * 2015-12-16 2017-06-22 株式会社 資生堂 タブレット型凍結乾燥化粧料
JP6404405B1 (ja) * 2017-06-14 2018-10-10 株式会社 資生堂 タブレット型凍結乾燥化粧料
CN110769810B (zh) * 2017-06-19 2023-08-01 株式会社资生堂 片剂型冷冻干燥化妆品
WO2021074182A1 (en) * 2019-10-14 2021-04-22 Inbiose N.V. Production of bioproduct in a host cell
CN116194460A (zh) * 2020-06-09 2023-05-30 Icosavax股份有限公司 制备病毒样颗粒的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1142940C (zh) * 1996-10-04 2004-03-24 安姆根有限公司 含有mpl配体的药物组合物
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
HU229148B1 (en) * 1999-03-09 2013-09-30 Zymogenetics Inc Seattle Human cytokine as ligand of the zalpha receptor and uses thereof
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
WO2003082212A2 (en) 2002-03-27 2003-10-09 The Governement Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method for treating cancer in humans
WO2003087320A2 (en) 2002-04-09 2003-10-23 Beth Israel Deaconess Medical Center, Inc. Antagonists of il-21 and modulation of il-21-mediated t cell responses
WO2004032953A1 (en) 2002-10-11 2004-04-22 Novo Nordisk A/S Treatment of allergic conditions by use of il 21
CN1513993A (zh) 2002-12-31 2004-07-21 北京博泰迪生物工程科技开发有限公司 中国人基因组cDNA文库白细胞介素21的编码基因序列及其蛋白质的氨基酸序列
WO2004112703A2 (en) 2003-06-19 2004-12-29 Centocor, Inc. Interleukin-21 analogs
WO2005049847A1 (en) 2003-11-24 2005-06-02 Novo Nordisk A/S Fusion proteins and methods of cleavage of such proteins

Also Published As

Publication number Publication date
US20070048842A1 (en) 2007-03-01
BR0317243A (pt) 2005-11-01
IL168697A (en) 2011-10-31
US7622561B2 (en) 2009-11-24
MXPA05006117A (es) 2005-09-30
ATE448298T1 (de) 2009-11-15
PL377291A1 (pl) 2006-01-23
US20070048263A1 (en) 2007-03-01
CA2507817C (en) 2014-04-22
NO20053385L (no) 2005-07-12
JP2006509525A (ja) 2006-03-23
IL198074A0 (en) 2011-08-01
ES2334127T3 (es) 2010-03-05
DK1573006T3 (da) 2010-03-22
EP1573006A2 (de) 2005-09-14
KR20050090393A (ko) 2005-09-13
AU2003302250B2 (en) 2009-08-27
CA2507817A1 (en) 2004-07-01
PL209009B1 (pl) 2011-07-29
JP4664684B2 (ja) 2011-04-06
AU2003302250A1 (en) 2004-07-09
KR101098897B1 (ko) 2011-12-26
EP1573006A4 (de) 2006-06-14
EP1573006B1 (de) 2009-11-11
NO334561B1 (no) 2014-04-07
US20060134754A1 (en) 2006-06-22
US7767199B2 (en) 2010-08-03
WO2004055168A3 (en) 2005-06-02
US7745176B2 (en) 2010-06-29
RU2354703C2 (ru) 2009-05-10
RU2005117338A (ru) 2006-03-20
US20070048798A1 (en) 2007-03-01
WO2004055168A2 (en) 2004-07-01
US7250274B2 (en) 2007-07-31

Similar Documents

Publication Publication Date Title
DE60330044D1 (de) Il-21-produktion in prokaryontischen wirten
HK1113161A1 (en) Fgf18 production in prokaryotic hosts
Lie et al. Essential anaplerotic role for the energy-converting hydrogenase Eha in hydrogenotrophic methanogenesis
AU2002311989A1 (en) Methods and materials for the production of organic products in cells of $i(candida) species
BR0115558A (pt) ácido nucleico isolado, construção de expressão recombinante, célula de levedura transformada com a construção de expressão recombinante, e, método para produzir ácido lático
EP1483281A4 (de) Verfahren zur herstellung interferierender rna-moleküle in säugetierzellen und therapeutische anwendungen solcher moleküle
DK2484758T3 (da) Rationelt konstruerede meganucleaser med ændret sekvensspecificitet og DNA-bindingsaffinitet
DE602006018969D1 (de) Herstellung und reinigung von il-29
BR0314498A (pt) Linhagens de e. coli e método para a bioprodução de 1,3-propanodiol
PE20060952A1 (es) Microorganismos productores de acido l-glutamico y metodo para la produccion de acido l-glutamico
MY156855A (en) Novel regulatory elements
AU2002251060A1 (en) Process for the production of l-amino acids using strains of the family enterobacteriaceae that contain an attenuated dgsa gene
IT1255044B (it) Procedimento per produrre glicosiltransferasi, vettore ibrido di lievito in esso impiegato e ceppo di lievito trasformato con impiego di vettore ibrido
MX2020012332A (es) Casetes de expresion de alfa-glucosidasa de acido optimizado con codon y metodos de uso del mismo.
DK1697522T3 (da) Plasmid opretholdelse
DK0939830T3 (da) Fremgangsmåde til forbedring af produktionen af et önsket produkt fra en celle
AR043862A1 (es) Procedimiento para la obtencion de estirpes celulares de mastocitos a partir de tejidos de cerdo y procedimiento para la produccion de moleculas de tipo de la heparina
WO2005034876A3 (en) Use of cell lines to produce active therapeutic proteins
Pilon et al. Ubiquitin fusion technology: bioprocessing of peptides
ATE382086T1 (de) Candida tropicalis cytochrom b5 gen und protein und verwendungen davon
AU2003260200A1 (en) Reversible, parallel and multitask cloning method and kit
HUP0202517A2 (hu) Az avermektinek B2:B1 arányát befolyásoló Streptomyces avermitilis gén
AU2002211021A1 (en) Method of searching for gene encoding nuclear transport protein
AU5049100A (en) Phage-dependent super-production of biologically active protein and peptides
KR920021708A (ko) 합성 유전자를 포함하는 신규한 유전자 운반체와 이를 이용한 인간 인터루킨-2의 제조 방법

Legal Events

Date Code Title Description
8364 No opposition during term of opposition